Market Cap | 9.24M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -12.69M | Forward P/E | -0.81 | EPS next Y | - | 50D Avg Chg | 9.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 47.00% |
Dividend | N/A | Price/Book | 0.68 | EPS next 5Y | - | 52W High Chg | -54.00% |
Recommedations | 3.00 | Quick Ratio | 4.12 | Shares Outstanding | 2.91M | 52W Low Chg | 122.00% |
Insider Own | 15.09% | ROA | -48.31% | Shares Float | 2.48M | Beta | 1.41 |
Inst Own | 6.24% | ROE | -83.97% | Shares Shorted/Prior | 14.57K/29.24K | Price | 3.18 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 901,977 | Target Price | - |
Oper. Margin | - | Earnings Date | Oct 2 | Volume | 15,341 | Change | -0.31% |
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.